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1  | INTRODUC TION
Seasonal influenza results in considerable morbidity and mortality, 
as well as increased healthcare utilization and costs.1 Each year, the 
disease leads to substantial losses in productivity for both patients 
and caregivers.2 The economic impact of influenza is of interest at 
both the microeconomic and the macroeconomic level.3 Although 
several studies have calculated the cost‐effectiveness of vaccination 
programs4 or applied modelling tools,5 precise data on the direct and 
indirect costs of influenza for a single institution are scarce. Here, we 
report an influenza outbreak in a rehabilitation centre and present 
its detailed microeconomic impacts.
2  | METHODS
2.1 | The outbreak
The institution Reha Chrischona (Bettingen, Switzerland) consists of 
75 beds (one‐bed or two‐bed room[s]) and provides between 19 000 
and 20 000 days of nursing care each year.6 Specialized in the field of 
internal medicine, musculoskeletal rehabilitation and oncology reha‐
bilitation, the institution employed 169 individuals in 2017. Standard 
precautions are applied to the care of all patients. Routine influenza 
vaccination is offered to healthcare workers without a mandatory 
vaccine policy. Influenza A subtype H3N2 was the predominantly 
circulating virus in the influenza season 2016/2017, the time interval 
defined to be from December 2016 to February 2017.7 The outbreak 
in the institution occurred in January 2017.
2.2 | Outbreak management
Influenza outbreak management was implemented as described 
elsewhere,8 after the detection of one confirmed influenza case and 
four patients with an influenza‐like illness (ILI). An ILI case defini‐
tion was implemented and included acute onset of new symptoms 
(ie,	within	24	hours).	The	presence	of	fever	(≥38°C)	and	cough,	or	
fever and other respiratory illness symptoms or fever without a rea‐
sonable alternative diagnosis was required to fulfil the case defini‐
tion.9 A rapid influenza diagnostic test (polymerase chain reaction 
[PCR], Xpert Flu, Cepheid) was performed in nasopharyngeal swab 
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Abstract
We report an influenza outbreak in a 75‐bed rehabilitation centre and present the 
detailed microeconomic impact that it had during the season 2016/2017. The di‐
rect medical, direct non‐medical and indirect costs were calculated. The outbreak 
included 18 patients with influenza and 8 contact patients, leading to 86 days with 
isolation precautions. During the outbreak month, 25 (15%) employees were absent 
from work for 89 days (mean 3.6 days, SD ± 1.8), and during the entire influenza sea‐
son 33 for 175 (5.3 ± SD 4.6) days, respectively. The economic burden related to the 
outbreak was 114 373 CHF (106 890 €, 112 131 $).
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specimens obtained from ILI cases. The influenza test result was 
communicated to both infection control specialists and healthcare 
personal of the institution within 24 hours. Daily active surveil‐
lance for acute respiratory illness among all patients and health‐
care personnel was started and continued for 18 days after the 
last laboratory‐confirmed influenza case was identified. Combined 
droplet‐contact isolation precautions were applied to all patients 
who fulfilled ILI case definitions. The importance of standard pre‐
cautions was stressed daily, and all healthcare personnel and visi‐
tors were requested to wear surgical masks and to perform hand 
hygiene before and after touching patients (irrespective of whether 
or not they had contact with an ILI case). Patients who fulfilled ILI 
case definitions remained in their private room or were discharged 
at home, depending on their health status and completion of reha‐
bilitation programme. If patient transport to another institution was 
necessary, patients had to wear surgical masks during the transport 
and information on the influenza test result was communicated. 
Isolation precautions in confirmed influenza cases were applied 
for at least five days after illness onset (at least ten days in immu‐
nocompromised patients) or until 24 hours after the resolution of 
fever	and	respiratory	symptoms,	whichever	was	longer.	Oseltamivir	
(75 mg) was administered twice daily to all patients who fulfilled 
the ILI case definition and was continued in laboratory‐confirmed 
cases for five days or in immunocompromised patients for ten days. 
PCR was repeated in immunocompromised patients with confirmed 
influenza after five or ten days of antiviral treatment. Patients ex‐
posed to a PCR‐positive influenza patient in the same patient room 
were pre‐emptively treated with oral oseltamivir (75 mg twice daily) 
for five days. Antiviral chemoprophylaxis was only offered to the 
defined patient group but not to all individuals.
2.3 | The economic burden
Data (direct costs and number of absentees from work per day dur‐
ing the outbreak) for the calculation of the economic burden were 
collected prospectively for this study. To calculate the economic 
burden, we estimated the direct medical costs, direct non‐medical 
costs and indirect costs.3 We defined direct medical costs as those 
associated with diagnostics and treatment of patients with ILI and 
their room neighbours (ie, contact patients). Direct non‐medical 
costs included the extra expense for droplet‐contact isolation pre‐
cautions. These costs were calculated in a previous investigation 
and extrapolated for this study.10 They included costs for extra 
materials used (eg, surgical masks, gloves, gowns), increased work‐
load and off isolation activities specifically for patients under isola‐
tion precautions.10 Indirect costs were defined as the value of lost 
production because of reduced working time for caregivers (pro‐
ductivity losses). We focussed only on the personnel in the institu‐
tion because the study targeted on the economic burden of the 
rehabilitation centre. The institution provided anonymized data for 
the numbers of employees and the number of work‐absence days 
during the outbreak month (January 2017). At the end of influenza 
season 2016/2017, an anonymized questionnaire was distributed 
to all employees to evaluate their vaccine status, whether they 
had been exposed to patients with influenza, whether they had 
experienced an ILI and the number of absence days from work be‐
cause of ILI. The completed questionnaires were collected by the 
investigators. Neither occupational health nor human resources 
of the rehabilitation centre had access to the questionnaires. The 
productivity loss was calculated as [days of absence] × [median 
salary for a specific profession within this institution]. The sum 
of productivity loss was calculated and provided by the chief ex‐
ecutive officer of the institution from the results generated by the 
questionnaire (Table 1). The currency of the productivity loss is 
Swiss Francs (CHF). The equivalent amount was calculated in Euros 
(1€ = 1.07 CHF) and US dollars (1$ = 1.02 CHF) on the basis of cur‐
rency indices in January 2017. Ethics committee approval was not 
required for this type of study.
3  | RESULTS
The number of patients with contact‐droplet isolation precau‐
tions per calendar day during the outbreak month is summarized in 
Figure 1A. Eighteen patients had laboratory‐confirmed influenza, 
and eight contact patients were identified. Two patients with labo‐
ratory‐confirmed influenza were referred to a tertiary care centre 
because of decompensated heart failure, after one day and five days 
with isolation precautions, respectively. Five patients with labora‐
tory‐confirmed influenza and one patient with ILI and negative 
influenza test result were discharged at home, because they were 
in good health and their rehabilitation programme was completed. 
Their periods with isolation precautions ranged from one day to 
five days prior to discharge. In total, 86 isolation precautions days 
were implemented in 18 days. An index case for the nosocomial out‐
break was not identified. None of the patients died. No new ILI case 
was observed after 7 days. The numbers of absentees per day dur‐
ing the outbreak month are shown in Figure 1B. In January 2017, 
TA B L E  1   Self‐reported work loss because of ILI during influenza 
season 2016/2017 at a rehabilitation centre
Profession/
Occupation
No. of 
 employees 
with ILI
No. of 
work days 
absent Mean ± SD
Nursing care 20 99 4.9 ± 4.1
Hotel sector, 
kitchen, laundry
4 28 7.0 ± 5.1
Physiotherapy, oc‐
cupational therapy
1 10 –
Social service 
employees
1 8 –
Othersa 7 30 4.3 ± 2.4
Total 33 175 5.3 ± 4.5
Abbreviation: ILI, influenza‐like illness.
aOthers	included	cleaning	service,	reception	and	administration,	patient	
support, volunteers. 
     |  3SENDI Et al.
F I G U R E  1   A, The number of patients with contact‐droplet isolation precautions per calendar day during the outbreak. B, Number of 
absentees per day during the outbreak month. The caregiver absent at January 2nd was not included in the study, because absence was 
more than 7 days prior to the start of the outbreak
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the employer reported that 25 (15%) employees were absent for 
89 days (mean 3.6 days, SD ± 1.8, range 1‐8 days per employee). 
The day with the highest numbers of patients with isolation precau‐
tions (16 January 2017; 12 individuals, Figure 1A) coincided with the 
day of the highest number of absentees from work (11 individuals, 
Figure 1B).
Of	the	distributed	questionnaires	(169),	158	were	returned	and	
150 (89%) were completed and included in the study. Hundred 
twenty (80%) of 150 employees were caregivers with patient con‐
tact, and 90 (60%) were exposed to patients with influenza. Twenty‐
three (15%) of 150 responders reported having been vaccinated 
against seasonal influenza.
Of	the	40	(of	150,	27%)	employees	who	reported	having	expe‐
rienced ILI during the season, three went for PCR testing and had 
laboratory‐confirmed influenza. Thirty‐three (22%) of 150 em‐
ployees reported absence from work for 175 days because of ILI. 
Twenty‐five (62.5%) of 40 employees with ILI were absent during 
the outbreak month, and 8 (33.3%) were absent in the other months 
of the influenza season. Seven employees with ILI reported no ab‐
sence; their disease period did not coincided with the working days. 
The mean self‐reported work loss because of ILI was 5.3 ± SD 4.6 
(range 1‐21) days. Seven (18%) of these 40 employees were vacci‐
nated against seasonal influenza. The distribution of the number of 
employees and the days absent from work per profession is shown 
in Table 1.
The direct costs related to the influenza outbreak are illustrated 
in Table 2. The sum of the calculated median loss of productiv‐
ity per profession for 40 employees was 87 000 CHF (81 308 €, 
82 294 $). The total economic burden related to the influenza season 
2016/2017 was 114 373 CHF (106 890 €, 112 131 $).
4  | DISCUSSION
The rapid infection control intervention was effective for the de‐
scribed	 influenza	outbreak.	Only	18	patients	with	 laboratory‐con‐
firmed influenza and eight contact patients were involved, and 
the outbreak period was short (18 days). It generated 27 373 CHF 
(25 582 €, 26 837 $) in direct costs to the institution. Influenza out‐
break management may differ in various aspects from institution to 
institution, and these differences influence direct costs. The Centers 
for Disease Control and Prevention (CDC) recommends to consider 
the use of antiviral chemoprophylaxis for all residents of long‐term 
care and post‐acute care facilities and to healthcare personnel.8 This 
approach may increase the direct costs for medication and the po‐
tential risk of resistance development as well as unwarranted drug 
effects and interactions with other compounds. The counter argu‐
ment includes reduction of transmission, because failure to control 
the outbreak will result in more nosocomial influenza cases and 
increased costs. The rehabilitation centre consisted of rooms only 
with one or two beds. Therefore, we focussed on rigorous hygiene 
precautions for patients, healthcare personal and visitors, and ad‐
ministered antiviral prophylaxis with a targeted approach. It is pos‐
sible that with a more generous use of antiviral prophylaxis, the 
infection control could have been even more efficient. However, we 
observed an excellent compliance for hygiene precautions among 
TA B L E  2   Economic burden of the influenza outbreak and loss of productivity
Currency Cost per item
Number of 
items
Total costs
CHF € $
Direct medical costs
Medication
Oseltamivir	for	ILI/influenza	casesa 7.50 270 2025   
Antiviral chemoprophylaxisa 7.50 80 600   
Diagnostics
PCR for influenza A/Bb 204 37 7548   
Total direct medical costs   10 173 9507 9974
Direct non‐medical costs
Costs for contact and droplet isolation per bed‐dayc 200 86 17 200 16 075 16 863
Total direct costs   27 373 25 582 26 837
Loss of productivityd 33 175 87 000 81 308 85 294
Total economic burden   114 373 106 890 112 131
Note: The equivalent amount of CHF was calculated in Euros (1€ = 1.07 CHF) and US dollars (1$ = 1.02 CHF) on the basis of currency indices in 
January 2017.
Aabbreviations: ILI, influenza‐like illness; PCR, polymerase chain reaction.
aVariable included oseltamivir for empiric treatment in ILI cases and for targeted treatment in influenza‐confirmed cases. Price per capsule in 2017. 
bCosts per item according to reference14 in 2017. 
cCosts per item were calculated in a previous investigation and extrapolated for this study.10 
dCalculated as [days of absence] × [median salary for a specific profession within this institution]. The sum of productivity loss was calculated on the 
basis of data provided in Table 1. 
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the healthcare personal and visitors. No new incidence case was de‐
tected one week after its implementation, and none of the patients 
required isolation precautions 16 days after implementation.
The productivity loss because of individuals with ILI is frequently 
reported on a macroeconomic level. Molinari et al2 estimated the 
productivity costs for influenza cases in the United States in 2003 
and projected lost earnings due to illness to be $16.3 billion (95% 
confidence interval, $8.7 to $31.0) annually. Putri et al11 recently 
published their results for 2015 and estimated indirect costs at 
$8.0 billion	and	‘days	of	productivity	lost'	at	$20.1	million.	We	pro‐
spectively focused on the microeconomic cost level at a single insti‐
tution. We used data from the employer and self‐reported data from 
the employees. The impact of influenza on work‐related absentee‐
ism can be reviewed from different perspectives in studies involving 
laboratory‐confirmed influenza, physician‐diagnosed ILI or self‐re‐
ported ILI.12 The reliability of self‐diagnosis may be lower than diag‐
nosis by a physician or confirmation by laboratory tests. However, 
all employees in our study were aware of the case definitions for 
ILI and the vast majority of absentees were caregivers and edu‐
cated about influenza. The mean reported work loss in our survey 
(5.3 ± SD 4.6 days per employee with ILI) was in the same range as 
in previous studies.12 Differences in the circulating influenza strains 
and the proportion of vaccinated individuals may influence the range 
of absence days because of ILI. Vaccine effectiveness against sea‐
sonal H3N2 in working‐age adults was reported to be 35%.13 We 
are unable to evaluate whether there was a shorter duration of work 
absence for vaccinated patients who contracted influenza than for 
unvaccinated employees. Nonetheless, the proportion of vaccinated 
employees was low (15%). Policy change and constant education for 
healthcare personal may potentially increase this proportion.
The study has limitations. We did not encounter the numbers of 
surgical masks and the volume disinfectant for hand hygiene used by 
visitors and personnel without patient contact. Thus, the direct non‐
medical costs are likely underestimated. The productivity loss data 
should be interpreted with caution, because there may be a recall 
bias of self‐reported absence and the anonymized questionnaire was 
not previously validated. Also, these data need to be analysed from a 
seasonal perspective over several years. Nonetheless, in this investi‐
gation, we demonstrated the financial damage at a single institution 
caused by an outbreak. In light of the cost pressure to which rehabil‐
itation centres are exposed, these data may have an implicit effect 
on influenza prevention strategies. These include programmes to 
increase the vaccination rates among healthcare personnel and pro‐
tocols for antiviral chemoprophylaxis. A detailed and rapid outbreak 
management concept against influenza may turn to be cost‐effec‐
tive, in particular for small institutions with limited resources.
ACKNOWLEDG EMENTS
We	 thank	 René	Gröflin	 (CEO),	 Gabriela	 Pflauma	 (RN,	 head	 nurse)	
and all employees of Bürgerspital Basel, Reha Chrischona, Bettingen, 
Switzerland, for their help during the outbreak and for providing 
data for the generation of this manuscript.
CONFLIC T OF INTERE S T
None.
ORCID
Parham Sendi  https://orcid.org/0000‐0002‐7347‐6312 
R E FE R E N C E S
 1. Neuzil KM, Maynard C, Griffin MR, Heagerty P. Winter respiratory 
viruses and health care use: a population‐based study in the north‐
west United States. Clin Infect Dis. 2003;37(2):201‐207.
	 2.	 Molinari	NA,	Ortega‐Sanchez	IR,	Messonnier	ML,	et	al.	The	annual	
impact of seasonal influenza in the US: measuring disease burden 
and costs. Vaccine. 2007;25(27):5086‐5096.
	 3.	 World	 Health	 Organization	 (WHO).	 WHO Manual for estimating 
the economic burden of seasonal influenza. Geneva: World Health 
Organization.	2016:63.
 4. Ting E, Sander B, Ungar WJ. Systematic review of the cost‐ef‐
fectiveness of influenza immunization programs. Vaccine. 
2017;35(15):1828‐1843.
 5. Adam T, Evans DB, Murray CJ. Econometric estimation of country‐
specific hospital costs. Cost Eff Resour Alloc. 2003;1(1):3.
 6. Bürgerspital Basel, Reha Chrischona, Bettingen. Jahresbericht 
2016. https ://www.reha.buespi.ch/files/ 80NUH WB/Jahre sberi 
cht‐Reha‐Chris chona‐2016.pdf. Accessed April 21, 2019.
 7. Bundesamt für Gesundheit. Saisonbericht Grippe 2016/2017. https 
://www.bag.admin.ch/dam/bag/de/.../saiso nberi cht‐grippe‐2016‐
17‐de.pdf. Accessed April 21, 2019.
 8. Centers for Disease Control and Prevention (CDC). Interim 
Guidance	for	Influenza	Outbreak	Management	in	Long‐Term	Care	
and Post‐Acute Care Facilities. Page last updated: February 12, 
2019; https ://www.cdc.gov/flu/profe ssion als/infec tionc ontro l/
ltc‐facil ity‐guida nce.htm. Accessed April 21, 2019.
 9. Call SA, Vollenweider MA, Hornung CA, Simel DL, McKinney WP. 
Does this patient have influenza? JAMA. 2005;293(8):987‐997.
 10. Roth JA, Hornung‐Winter C, Radicke I, et al. Direct costs of a con‐
tact isolation day: a prospective cost analysis at a Swiss university 
hospital. Infect Control Hosp Epidemiol. 2018;39(1):101‐103.
 11. Putri W, Muscatello DJ, Stockwell MS, Newall AT. Economic 
burden of seasonal influenza in the United States. Vaccine. 
2018;36(27):3960‐3966.
 12. Keech M, Beardsworth P. The impact of influenza on work‐
ing days lost: a review of the literature. Pharmacoeconomics. 
2008;26(11):911‐924.
 13. Belongia EA, Simpson MD, King JP, et al. Variable influenza 
vaccine effectiveness by subtype: a systematic review and 
meta‐analysis of test‐negative design studies. Lancet Infect Dis. 
2016;16(8):942‐951.
 14. Bundesamt für Gesundheit. Analysenliste 2017. https ://www.
bag.admin.ch/bag/de/home/versi cheru ngen/krank enver siche 
rung/krank enver siche rung‐leist ungen‐tarif e/Analy senli ste.html. 
Accessed April 21, 2019.
How to cite this article: Sendi P, Dräger S, Batzer B, Walser S, 
Dangel M, Widmer AF. The financial burden of an influenza 
outbreak in a small rehabilitation centre. Influenza Other Respi 
Viruses. 2019;00:1–5. https ://doi.org/10.1111/irv.12696 
